| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | https://www.pghealthindia.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 9,174.15 Cr. | |
| Earnings per share (EPS) | 115.53 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 47.84 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 32.75 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 398.00 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 13.89 | Calculated using Price: 5,526.80 |
| Dividend Yield | 4.16 | Period Ending 2020-06 |
| No. of Shares Subscribed | 1.66 Cr. | 16,599,382 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Procter & Gamble Health Limited (formerly Merck Limited) was set up in India as one of Merck’s Asian subsidiaries in 1967. It was also the first Merck Group Company to go public in the year 1981. Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country. On December 1st, 2018, P&G successfully completed the acquisition of Merck’s Consumer Health business further to approval of all relevant regulatory authorities and the fulfilment of other customary closing conditions. Procter & Gamble Overseas India B.V. now holds 51.81% of the share capital in Merck Limited, while the remaining 48.19% is traded on the Bombay Stock Exchange Ltd. and National Stock Exchange of India Ltd. Currently, Procter & Gamble Health Limited (formerly Merck Limited) is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life. With a strong portfolio of brands backed by science and trusted by doctors, pharmacists and consumers, Procter & Gamble Health Limited combines the best of P&G and Legacy Merck’s Consumer Health capabilities and cultures. Together we are working towards leveraging our combined expertise to develop categories and brands that meet today’s needs and tomorrow’s opportunities. Situated at Usgaon, Goa, the company’s Manufacturing Site has grown from a small Vitamin E producing unit to a big composite plant manufacturing pharma and chemical products. Business area of the company Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country. The company is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life. Brands of the company
Awards and achievements
|
||
Company Profile
Procter & Gamble Health Limited (formerly Merck Limited) was set up in India as one of Merck’s Asian subsidiaries in 1967. It was also the first Merck Group Company to go public in the year 1981. Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country.
On December 1st, 2018, P&G successfully completed the acquisition of Merck’s Consumer Health business further to approval of all relevant regulatory authorities and the fulfilment of other customary closing conditions. Procter & Gamble Overseas India B.V. now holds 51.81% of the share capital in Merck Limited, while the remaining 48.19% is traded on the Bombay Stock Exchange Ltd. and National Stock Exchange of India Ltd.
Currently, Procter & Gamble Health Limited (formerly Merck Limited) is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life. With a strong portfolio of brands backed by science and trusted by doctors, pharmacists and consumers, Procter & Gamble Health Limited combines the best of P&G and Legacy Merck’s Consumer Health capabilities and cultures. Together we are working towards leveraging our combined expertise to develop categories and brands that meet today’s needs and tomorrow’s opportunities.
Situated at Usgaon, Goa, the company’s Manufacturing Site has grown from a small Vitamin E producing unit to a big composite plant manufacturing pharma and chemical products.
Business area of the company
Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country. The company is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life.
Brands of the company
Awards and achievements
| 1 Day |
|
+0.42% |
| 1 Week |
|
+2.33% |
| 1 Month |
|
-2.15% |
| 3 Month |
|
-12.48% |
| 6 Month |
|
-22.87% |
| 1 Year |
|
+25.26% |
| 2 Year |
|
+17.19% |
| 5 Year |
|
+689.06% |
| 9 years | 2011-12 | 2012-12 | 2013-12 | 2014-12 | 2015-12 | 2016-12 | 2017-12 | 2018-12 | 2020-06 | |
| Return on Equity (%) | 16.84 | 17.54 | 11.10 | 8.02 | 9.35 | 12.61 | 13.44 | 73.79 | 20.79 | |
| Return on Capital Employed (%) | 25.30 | 26.14 | 17.53 | 12.36 | 14.54 | 18.35 | 21.79 | 80.76 | 29.01 | |
| Return on Assets (%) | 9.57 | 8.16 | 6.71 | 4.67 | 3.92 | 5.48 | 6.52 | 40.93 | 10.82 |
| Particulars | 9 years | 2011-12 Rs. Cr. | 2012-12 Rs. Cr. | 2013-12 Rs. Cr. | 2014-12 Rs. Cr. | 2015-12 Rs. Cr. | 2016-12 Rs. Cr. | 2017-12 Rs. Cr. | 2018-12 Rs. Cr. | 2020-06 Rs. Cr. |
| Shh. Funds | 410 | 484 | 523 | 554 | 592 | 664 | 733 | 1,540 | 906 | |
| Non Curr. Liab. | 13 | 338 | 13 | 390 | 395 | 399 | 431 | 495 | 667 | |
| Curr. Liab. | 481 | 195 | 112 | 260 | 539 | 301 | 352 | 548 | 539 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 904 | 1,016 | 648 | 1,204 | 1,525 | 1,363 | 1,516 | 2,583 | 2,112 | |
| Non Curr. Assets | 120 | 460 | 171 | 581 | 579 | 613 | 637 | 693 | 845 | |
| Curr. Assets | 784 | 557 | 478 | 623 | 946 | 750 | 879 | 1,889 | 1,267 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 904 | 1,016 | 648 | 1,204 | 1,525 | 1,363 | 1,516 | 2,583 | 2,112 |
| Particulars | 9 years | 2011-12 Rs. Cr. | 2012-12 Rs. Cr. | 2013-12 Rs. Cr. | 2014-12 Rs. Cr. | 2015-12 Rs. Cr. | 2016-12 Rs. Cr. | 2017-12 Rs. Cr. | 2018-12 Rs. Cr. | 2020-06 Rs. Cr. |
| Net Sales | 590 | 687 | 798 | 867 | 940 | 993 | 698 | 1,288 | 1,356 | |
| Other Income | 31 | 20 | 21 | 20 | 23 | 24 | 84 | 722 | 70 | |
| Total Income | 621 | 707 | 819 | 888 | 963 | 1,017 | 782 | 2,010 | 1,426 | |
| Total Expenditure | -517 | -582 | -721 | -809 | -856 | -877 | -628 | -1,078 | -1,042 | |
| PBIDT | 104 | 126 | 98 | 79 | 107 | 140 | 154 | 932 | 384 | |
| Interest | 0 | |||||||||
| Depreciation | -8 | -9 | -10 | -13 | -23 | -25 | -19 | -21 | -29 | |
| Taxation | -32 | -38 | -32 | -23 | -30 | -36 | -58 | -79 | -101 | |
| Exceptional Items | 17 | 7 | ||||||||
| PAT | 64 | 78 | 56 | 43 | 54 | 79 | 94 | 839 | 254 |
| Particulars | 9 years | 2011-12 Rs. Cr. | 2012-12 Rs. Cr. | 2013-12 Rs. Cr. | 2014-12 Rs. Cr. | 2015-12 Rs. Cr. | 2016-12 Rs. Cr. | 2017-12 Rs. Cr. | 2018-12 Rs. Cr. | 2020-06 Rs. Cr. |
| Cash Fr. Operatn. | 19 | 54 | 0 | 5 | 83 | 107 | 54 | -130 | 235 | |
| Cash Fr. Inv. | -9 | -82 | 7 | 11 | -68 | -75 | -48 | 1,270 | 165 | |
| Cash Fr. Finan. | 0 | -5 | -17 | -12 | -15 | -22 | -30 | -883 | ||
| Net Change | 10 | -28 | 3 | -1 | 4 | 17 | -16 | 1,109 | -483 | |
| Cash & Cash Eqvt | 31 | 4 | 7 | 5 | 9 | 26 | 10 | 1,119 | 636 |
|
Wed, 28 Jul 2021
Disclosure: SEBI Circular No SEBI/HO/DDHS/CIR/P/2018/144 Dated November 26 2018 With Respect To Disclosure Of Fund Raising By Issuance Of Debt Securities By Large Entities. We refer to the SEBI Circular No SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018 with respect to fund raising by issuance of Debt Securities by large entities and disclosures thereof by such large entities. In this regard we wish to inform you that the Company does not fall under the criteria as specified in para 2.2 of the said SEBI Circular. Hence our Company does not classify as a Large Corporate under the framework provided in the above-mentioned circular for the financial year 2020-21. |
|
Tue, 27 Jul 2021
Certificate Under Regulation 40(9) Of The SEBI Listing Regulations. With reference to the above we are enclosing herewith Certificate under Regulation 40(9) of the SEBI Listing Regulations for the year ended June 30 2021. |
|
Tue, 20 Jul 2021
Shareholding for the Period Ended June 30 2021 Procter & Gamble Health Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here |
| Wed, 04 Aug 2021 |
Opening at High
|
Making Higher Highs for 3 days
|
MFI Below 20
|
| Tue, 03 Aug 2021 |
Closing Above Previous High
|
|
MFI Below 20
|
Equities
M.F.
Sectors